Efficacy and Safety of 7 Days Versus 10 Days Triple Therapy Based on Levofloxacin-dexlansoprazole for Eradication of : A Pilot Randomized Trial

Overview

Journal Indian J Pharmacol

Specialty Pharmacology

Date 2020 Dec 7

PMID 33283766

Citations 1

Authors

Noha Mahmoud Elkhodary

Khaled Abdalkader Farrag

Amany Mahmoud Elokaby

Gamal Abd El-Hay Omran

Affiliations

Soon will be listed here.

Abstract

Background: Levofloxacin-based triple therapies are considered the standard regimen for eradication of Helicobacter pylori (H. pylori) due to decreased sensitivity to clarithromycin and the optimal duration of therapy is still controversial. Besides, there is no complete evidence about dexlansoprazole efficacy in the eradication of H. pylori.

Aim: Our study aimed to determine the effectiveness of triple therapy based on levofloxacin-dexlansoprazole as a standard treatment for H. pylori infection and estimate the effect of H. pylori on lipid profile and hemoglobin (Hb).

Materials And Methods: A pilot prospective randomized trial of a triple therapy based on levofloxacin-dexlansoprazole for H. pylori eradication was conducted at Damanhour Medical National Institute, Egypt; 66 participants with H. pylori infection received levofloxacin (500 mg/day) plus amoxicillin (1 g/12 h) plus dexlansoprazole (60 mg/day). All medications administrated orally for either 7 days or 10 days. Four weeks after treatment, the eradication was assessed by the stool antigen test.

Results: The rate of eradication was 63.6% in levofloxacin, amoxicillin, and dexlansoprazole (LAD) 7-day group, and 90.9% in LAD 10-day group. In addition, laboratory test results showed a significant difference in Hb, low-density lipoprotein, high-density lipoprotein, triglyceride, and total cholesterol levels before and after treatment (P < 0.05).

Conclusion: LAD 10 days is the least duration that provides maximum efficacy for H. pylori in Egyptian participants. In addition, successful treatment of H. pylori infection may reduce the risk of anemia and dyslipidemia. Furthermore, all members of the patient's family should be screened for H. pylori to prevent recurrent infection.

Citing Articles

Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.

Fekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S BMC Gastroenterol. 2023; 23(1):55.

PMID: 36882697 PMC: 9990047. DOI: 10.1186/s12876-023-02707-5.

References

Sharma P, Shaheen N, Perez M, Pilmer B, Lee M, Atkinson S . Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29(7):731-41. DOI: 10.1111/j.1365-2036.2009.03933.x. View

Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E . Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016; 16(1):80. PMC: 4962503. DOI: 10.1186/s12876-016-0491-7. View

Chey W, Leontiadis G, Howden C, Moss S . ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2):212-239. DOI: 10.1038/ajg.2016.563. View

Qu X, Huang X, Xiong P, Zhu C, Huang Y, Lu L . Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010; 16(7):886-96. PMC: 2825337. DOI: 10.3748/wjg.v16.i7.886. View

Shin J, Kim N . Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013; 19(1):25-35. PMC: 3548122. DOI: 10.5056/jnm.2013.19.1.25. View

Leja M, Grinberga-Derica I, Bilgilier C, Steininger C . Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019; 24 Suppl 1:e12635. DOI: 10.1111/hel.12635. View

Wu D, Kuo C, Tsay F, Hsu W, Chen A, Hsu P . A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore). 2016; 95(11):e2698. PMC: 4839877. DOI: 10.1097/MD.0000000000002698. View

Iwanczak F, Iwanczak B . Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med. 2013; 21(5):671-80. View

Ahn H, Kim D, Chu M, Yun H, Kim S, Lee S . Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Infections. Gastroenterol Res Pract. 2017; 2017:1654907. PMC: 5429953. DOI: 10.1155/2017/1654907. View

10.

Mitchell H, Katelaris P . Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016; 204(10):376-80. DOI: 10.5694/mja16.00104. View

11.

Hudak L, Jaraisy A, Haj S, Muhsen K . An updated systematic review and meta-analysis on the association between Helicobacter pylori infection and iron deficiency anemia. Helicobacter. 2016; 22(1). DOI: 10.1111/hel.12330. View

12.

Scott D, Sachs G, Marcus E . The role of acid inhibition in eradication. F1000Res. 2018; 5. PMC: 4957631. DOI: 10.12688/f1000research.8598.1. View

13.

Korkmaz H, Kesli R, Karabagli P, Terzi Y . Comparison of the diagnostic accuracy of five different stool antigen tests for the diagnosis of Helicobacter pylori infection. Helicobacter. 2013; 18(5):384-91. DOI: 10.1111/hel.12053. View

14.

Eusebi L, Zagari R, Bazzoli F . Epidemiology of Helicobacter pylori infection. Helicobacter. 2014; 19 Suppl 1:1-5. DOI: 10.1111/hel.12165. View

15.

Sousa J, Etchebehere R, de Magalhaes Queiroz D, Fonseca F, Batista B, Junqueira I . Increased serum gastrin in patients with different clinical forms of Chagas disease coinfected with Helicobacter pylori. Rev Inst Med Trop Sao Paulo. 2019; 61:e7. PMC: 6376922. DOI: 10.1590/S1678-9946201961007. View

16.

Haji-Aghamohammadi A, Bastani A, Miroliaee A, Oveisi S, Safarnezhad S . Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection. Caspian J Intern Med. 2016; 7(4):267-271. PMC: 5153518. View

17.

OConnor A, Lamarque D, Gisbert J, OMorain C . Treatment of Helicobacter pylori infection 2017. Helicobacter. 2017; 22 Suppl 1. DOI: 10.1111/hel.12410. View

18.

Nam S, Ryu K, Park B, Park S . Effects of Helicobacter pylori infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter. 2014; 20(2):125-32. DOI: 10.1111/hel.12182. View

19.

Eshraghian A . Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: a systematic review of prevalence and risk factors. World J Gastroenterol. 2014; 20(46):17618-25. PMC: 4265624. DOI: 10.3748/wjg.v20.i46.17618. View

20.

Rostami-Nejad M, Aldulaimi D, Livett H, Rostami K . H.pylori associated with iron deficiency anemia even in celiac disease patients; strongly evidence based but weakly reflected in practice. Gastroenterol Hepatol Bed Bench. 2015; 8(3):178-82. PMC: 4553157. View